Cash-back rewards platform Ibotta (NYSE:IBTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales ...

Fintel reports that on August 14, 2025, B of A Securities downgraded their outlook for Ibotta (NYSE:IBTA) from Neutral to ...

Fintel reports that on August 14, 2025, Goldman Sachs downgraded their outlook for Ibotta (NYSE:IBTA) from Buy to Neutral.

The projected fair value for Ibotta is US$39.53 based on 2 Stage Free Cash Flow to Equity. Ibotta's US$23.62 share price signals that it might be 40% undervalued. Ou ...

Ibotta Inc (IBTA) focuses on strategic transformation and client engagement despite short-term revenue challenges.

Ibotta reports declining revenue & margins, ending growth streak. User growth remains strong, but monetization drops, ...

Ibotta, Inc. ( NYSE: IBTA) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Bryan W. Leach - Founder, President, CEO & Chairman Valarie L. Sheppard - Interim CFO & Director ...

ARK’s ARKK ETF also added 165,024 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) to its portfolio, valued at $9,706,711. The ...

Ibotta(NYSE:IBTA) reported second quarter 2025 earnings on August 13, 2025, with revenue of $86 million, a 2% year-over-year decline, and adjusted EBITDA of $17.9 million. Management cited a 48% ...

Ibotta shares plunged 34% after Q2 earnings missed forecasts, prompting multiple analyst downgrades and price target cuts.

Ibotta (IBTA) shares cratered 34% after a string of Wall Street downgrades followed a much weaker-than-expected second quarter and bleak outlook.

The ARKK ETF further diversified its portfolio with the purchase of 80,619 shares of ILLUMINA INC (NASDAQ:ILMN), a leader in genomic sequencing, for $7,914,483. This investment signals ARK’s sustained ...